JP2013518910A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518910A5
JP2013518910A5 JP2012552143A JP2012552143A JP2013518910A5 JP 2013518910 A5 JP2013518910 A5 JP 2013518910A5 JP 2012552143 A JP2012552143 A JP 2012552143A JP 2012552143 A JP2012552143 A JP 2012552143A JP 2013518910 A5 JP2013518910 A5 JP 2013518910A5
Authority
JP
Japan
Prior art keywords
compound
formula
salt
acid
reducing reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012552143A
Other languages
English (en)
Japanese (ja)
Other versions
JP5735988B2 (ja
JP2013518910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/023965 external-priority patent/WO2011097602A1/en
Publication of JP2013518910A publication Critical patent/JP2013518910A/ja
Publication of JP2013518910A5 publication Critical patent/JP2013518910A5/ja
Application granted granted Critical
Publication of JP5735988B2 publication Critical patent/JP5735988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012552143A 2010-02-08 2011-02-08 ジヒドロピリドフタラジノン誘導体を合成する方法 Active JP5735988B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30245710P 2010-02-08 2010-02-08
US61/302,457 2010-02-08
PCT/US2011/023965 WO2011097602A1 (en) 2010-02-08 2011-02-08 Processes of synthesizing dihydropyridophthalazinone derivatives

Publications (3)

Publication Number Publication Date
JP2013518910A JP2013518910A (ja) 2013-05-23
JP2013518910A5 true JP2013518910A5 (enExample) 2014-03-27
JP5735988B2 JP5735988B2 (ja) 2015-06-17

Family

ID=44354222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012552143A Active JP5735988B2 (ja) 2010-02-08 2011-02-08 ジヒドロピリドフタラジノン誘導体を合成する方法

Country Status (21)

Country Link
US (2) US8765945B2 (enExample)
EP (1) EP2533640B1 (enExample)
JP (1) JP5735988B2 (enExample)
KR (1) KR101826652B1 (enExample)
CN (1) CN102834008B (enExample)
AU (1) AU2011213584B2 (enExample)
BR (1) BR112012019648B1 (enExample)
CA (1) CA2788114C (enExample)
CY (1) CY1118575T1 (enExample)
DK (1) DK2533640T3 (enExample)
ES (1) ES2606174T3 (enExample)
HU (1) HUE030794T2 (enExample)
IL (1) IL221170A (enExample)
MX (1) MX340319B (enExample)
PL (1) PL2533640T3 (enExample)
PT (1) PT2533640T (enExample)
RU (1) RU2561732C2 (enExample)
SG (1) SG182784A1 (enExample)
SI (1) SI2533640T1 (enExample)
WO (1) WO2011097602A1 (enExample)
ZA (1) ZA201205538B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012976B2 (en) 2008-08-06 2011-09-06 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
US8541403B2 (en) 2010-02-03 2013-09-24 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
DK2533640T3 (en) 2010-02-08 2017-01-23 Medivation Technologies Inc METHODS OF SYNTHESIS OF DIHYDROPYRIDOPHTHALAZINE DERIVATIVES
PL2630146T3 (pl) 2010-10-21 2020-11-02 Medivation Technologies Llc Krystaliczna sól tosylanowa (8S,9R)-5-fluoro-8-(4-fluorofenylo)-9-(1-metylo-1H-1,2,4-triazol-5-ilo)-8,9-dihydro-2H-pirydo[4,3,2-de]ftalazyno-3(7H)-onu
JP2016529284A (ja) 2013-08-27 2016-09-23 ノースイースタン ユニバーシティ ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法
EP3066084A1 (en) * 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
EA201790290A1 (ru) * 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
CN104557917A (zh) * 2014-12-12 2015-04-29 重庆博腾制药科技股份有限公司 一种5-卤代氮杂环吲哚的制备方法
JP6786761B2 (ja) * 2015-05-26 2020-11-18 ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. Sfcによるキラル異性体の分離
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
EP3694551A1 (en) 2017-10-13 2020-08-19 Merck Patent GmbH Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US20210355223A1 (en) 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
EP4243785B1 (en) 2020-11-13 2026-04-08 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
EP4256088A1 (en) 2020-12-07 2023-10-11 Pfizer Inc. Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
KR20230159510A (ko) 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2025210510A1 (en) 2024-04-04 2025-10-09 Pfizer Inc. Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd 2−キノロン誘導体
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) * 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
US7402580B2 (en) 2002-02-19 2008-07-22 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
JPWO2004043959A1 (ja) 2002-11-12 2006-03-09 持田製薬株式会社 新規parp阻害剤
AU2004220321B2 (en) 2003-03-12 2010-02-25 Kudos Pharmaceuticals Ltd Phthalazinone derivatives
WO2004105700A2 (en) 2003-05-28 2004-12-09 Guildford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
US7269138B2 (en) * 2003-06-04 2007-09-11 Motorola, Inc. Distributed MAC protocol facilitating collaborative ranging in communications networks
CN101845023A (zh) 2004-02-18 2010-09-29 阿斯利康(瑞典)有限公司 四唑化合物及其作为代谢型谷氨酸受体拮抗剂的应用
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR20100007956A (ko) 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
BRPI0721950A2 (pt) 2007-08-22 2015-09-29 4Sc Ag indolopiridinas como inibidores da proteína de fuso de cinesina
MX2010003564A (es) * 2007-10-03 2010-09-10 Eisai Inc Compuestos inhibidores de poli(adenosina-5'-difosfo-ribosa)polimer asa (parp), composiciones y metodos de uso.
WO2009099736A2 (en) 2008-02-06 2009-08-13 Lead Therapeutics, Inc. Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
US8012976B2 (en) * 2008-08-06 2011-09-06 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
MX2011001563A (es) 2008-08-12 2011-03-04 Boehringer Ingelheim Int Procedimiento para la preparacion de compuestos de piperazina sustituidos con cloalquilo.
US8541403B2 (en) 2010-02-03 2013-09-24 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
DK2533640T3 (en) 2010-02-08 2017-01-23 Medivation Technologies Inc METHODS OF SYNTHESIS OF DIHYDROPYRIDOPHTHALAZINE DERIVATIVES
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
PL2630146T3 (pl) 2010-10-21 2020-11-02 Medivation Technologies Llc Krystaliczna sól tosylanowa (8S,9R)-5-fluoro-8-(4-fluorofenylo)-9-(1-metylo-1H-1,2,4-triazol-5-ilo)-8,9-dihydro-2H-pirydo[4,3,2-de]ftalazyno-3(7H)-onu
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
EP3066084A1 (en) 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения

Similar Documents

Publication Publication Date Title
RU2012138345A (ru) Способы синтеза производных дигидропиридофталазинона
JP5923105B2 (ja) キラルスピロ−ピリジルアミドフォスフィン配位子化合物、その合成方法及びその利用
Fu et al. Nickel‐Catalyzed Difluoromethylation of Arylboronic Acids with Bromodifluoromethane
EP2582671A2 (en) Process for the preparation of a single enantiomer of 3-aminopiperidine dihydrochloride
US10899681B2 (en) Process for the preparation of deuterated ethanol from D2
Tran et al. Development of a Commercial Process for Odalasvir
JP2014520075A5 (enExample)
Zhang et al. Copper-catalyzed carbonylative Suzuki-Miyaura coupling of un-activated alkyl bromides with aryl boronates
CN106674264A (zh) (2,2,2‑三氟乙氧基)苯硼酸类化合物的合成方法
JP6213417B2 (ja) 2,2−ジフルオロアセトアルデヒドの保存安定性の向上方法
JP5646706B2 (ja) C−グリコシド誘導体の製造方法
JPWO2007013698A1 (ja) アルジミンまたはその誘導体を用いる一置換アルキル化化合物の製造方法
JP2013010705A (ja) フルオロ硫酸芳香環エステル類の製造方法
JP5663605B2 (ja) アミノフェニルピリミジニルアルコール誘導体の製造方法及びその合成中間体
Napolitano et al. Synthesis, kinase activity and molecular modeling of a resorcylic acid lactone incorporating an amide and a trans-enone in the macrocycle
JP6615212B2 (ja) 1−(2−ハロゲン−エチル)−4−ピぺリジンカルボン酸エチルエステルの製法
JP4839724B2 (ja) 光学活性α−フルオロカルボン酸エステル誘導体の製造方法
US20110282077A1 (en) Process for producing optically active alcohol
CN119191996A (zh) 一种双羟乙基氨基丙基羟乙基油胺的合成方法
CN103333123B (zh) 一种二氢喹唑啉酮化合物的脱卤方法
JP6871802B2 (ja) 不均一系パラジウム触媒存在下でアルデヒドを一酸化炭素源として用いるハロゲン化合物のカルボニル化反応によりカルボニル化合物を得る方法
CN114805172B (zh) 一种合成非对称杂环二芳基甲烷类化合物的方法
WO2024169071A1 (zh) 不对称催化氢化制备沙库巴曲化合物的方法
JP5077797B2 (ja) ホモアリルアルコールの製造方法、及び不斉触媒
JP6235932B2 (ja) 2−シアノフェニルボロン酸誘導体の製造方法